📢 We are proud to share two recent open access scientific publications to which IMPACT EU project has contributed, supporting groundbreaking research on arrhythmogenic cardiomyopathy (ACM).
🔬 The review “Advances in arrhythmogenic cardiomyopathy modeling using human-induced pluripotent stem cell-based models” explores the latest progress in developing hiPSC-based models for ACM. Both 2D and 3D models are discussed, showing their ability to replicate key pathological features and their potential to uncover mechanisms and test innovative therapies.
👉 Read the full article here: https://www.heartrhythmjournal.com/article/S1547-5271(25)02753-5/fulltext
💊 The study “Givinostat inhibits in vitro differentiation of cardiac fibroadipogenic precursors from a mouse model of arrhythmogenic cardiomyopathy”, published in Biomedicine & Pharmacotherapy, shows how the drug Givinostat – a histone deacetylase inhibitor already approved for other conditions – can reduce proliferation and differentiation of cardiac fibroadipogenic precursors (cFAPs), the cells responsible for the fibro-fatty replacement typical of ACM. These findings open promising avenues for future targeted therapies.
👉 Read the full article here: https://doi.org/10.1016/j.biopha.2025.118549
🌍 These articles represent the tangible results that the IMPACT EU project is bringing to ACM research, expanding knowledge and opening new therapeutic perspectives!
Università degli Studi di Padova, Leiden University Medical Center, Italfarmaco
Alessandra Rampazzo, Martina Calore, Sara Vencato, Chiara Romanato, Angelo Velle, Nicola Facchinello, Paola Braghetta, Chiara Romualdi, Libero Vitiello, Simonetta Andrea Licandro, Christian Steinkuhler, Monica Forino, Gianluca Fossati
